Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemetrexed - Eli Lilly

Drug Profile

Pemetrexed - Eli Lilly

Alternative Names: Alimta; LY-231514; LY-231514 disodium; MTA; Multitargeted antifolate; Pemetrexed disodium

Latest Information Update: 04 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Merck Sharp & Dohme; University of California, Davis; Virginia Commonwealth University
  • Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer
  • Phase I/II Solid tumours
  • No development reported Head and neck cancer; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Renal cell carcinoma
  • Discontinued Small cell lung cancer

Most Recent Events

  • 31 Jan 2019 The US FDA approves pemetrexed for Non small cell lung cancer with no EGFR or ALK genomic tumor aberrations (First-line therapy, Combination therapy) in USA
  • 31 Jan 2019 Efficacy and adverse events data fromthe phase III KEYNOTE-189 trial for Non small cell lung cancer (First line, Combination therapy) released by Eli Lily
  • 19 Oct 2018 Safety and efficacy data from a phase III trial in Non-small cell lung cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top